Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$21.88 USD
-0.34 (-1.53%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $21.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth C Momentum D VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 37% (94 out of 251)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.00 | 1.58 | 9.99 |
Current Quarter Estimate | -0.55 | -1.22 | 61.00 |
Year Ago Quarter Estimate | -0.51 | -0.07 | 54.84 |
Next Quarter Estimate | -0.57 | -1.93 | 63.00 |
Next Year Estimate | -2.44 | 12.53 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | -0.50 | 20.20 | 15.67 |
Next Year | -20.79 | 15.20 | 11.34 |
Last 5 Years | NA | 7.90 | 8.10 |
Next 5 Years | NA | 21.70 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -3.93 |
Price/Book (MRQ) | 3.38 | 1.61 |
Price/Cash Flow (MRFY) | NA | 9.71 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | NA | -58.89% |
Return on Equity (TTM) | -29.31% | -58.99% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.